a Direction des Risques Biologiques et de La Santé au Travail, Institut National de Santé Publique du Québec , Montréal and Québec , Québec , Canada.
b Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du CHU de Québec , Québec , Canada.
Hum Vaccin Immunother. 2018 Jan 2;14(1):118-123. doi: 10.1080/21645515.2017.1385688. Epub 2017 Dec 13.
In Quebec, Canada, a school-based HPV vaccination for girls has been offered since 2008. The vaccine used in the program targets HPV16/18, responsible for ∼70% of cervical cancers and HPV6/11, responsible for the majority of anogenital warts. The objective of this study was to assess the prevalence of HPV in vaccinated and unvaccinated women.
Women aged 17-29 years were eligible to participate. Participants' age, vaccination status and diverse risk factors were assessed by a computer-assisted questionnaire. Biological specimens were obtained by self-sampling. HPV genotyping was performed by Linear Array.
A total of 2,118 women were recruited. 2,042 completed the questionnaire and 1,937 provided a vaginal sample. Vaccination coverage varied from 83.5% in women aged 17-19 to 19.1% in those aged 23-29. The overall prevalence of HPV in sexually active women was 39.4% (95%CI: 37.0-41.7) and 56.7% of infected women had multiple type infections. The prevalence of vaccine HPV types varied by age and vaccination status except for women aged 23-29 for whom similar results were observed. Vaccine HPV types were detected in 0.3%, 1.4% and 10.5% of vaccinated women aged 17-19, 20-23, and 23-29 (p<0.05), respectively. HPV16 or HPV18 were detected in 10 women having received at least one dose of vaccine. Nine of these women were already sexually active at the time of vaccination.
Infections with HPV types included in the vaccine are rare in women aged less than 23 years and are virtually absent in those who received at least one dose of vaccine before sexual debut.
在加拿大魁北克省,自 2008 年以来,已经为女孩提供了基于学校的 HPV 疫苗接种。该计划中使用的疫苗针对 HPV16/18,其导致约 70%的宫颈癌,HPV6/11 导致大多数肛门生殖器疣。本研究的目的是评估接种和未接种疫苗的女性中 HPV 的流行率。
年龄在 17-29 岁的女性有资格参加。通过计算机辅助问卷评估参与者的年龄、疫苗接种状况和各种危险因素。通过自我采样获得生物标本。通过线性阵列进行 HPV 基因分型。
共招募了 2118 名女性。2042 名完成了问卷,1937 名提供了阴道样本。疫苗接种率在 17-19 岁的女性中为 83.5%,在 23-29 岁的女性中为 19.1%。性活跃女性 HPV 的总体流行率为 39.4%(95%CI:37.0-41.7),56.7%的感染女性有多种类型感染。疫苗 HPV 类型的流行率因年龄和疫苗接种状况而异,但 23-29 岁的女性除外,她们观察到相似的结果。17-19 岁、20-23 岁和 23-29 岁接种疫苗的女性中,疫苗 HPV 类型分别在 0.3%、1.4%和 10.5%的接种女性中检测到(p<0.05)。在至少接种一剂疫苗的 10 名女性中检测到 HPV16 或 HPV18。这些女性中有 9 人在接种疫苗时已经有性行为。
在 23 岁以下的女性中,疫苗中包含的 HPV 类型的感染很少见,在性活跃前至少接种一剂疫苗的女性中几乎不存在。